Weill Cornell Newsroom > Press Releases
$4 million grant gives Columbia, Weill Cornell Medicine, NewYork-Presbyterian, and NYC Health + Hospitals key role in precision medicine cohort program
|Dr. Mark Rubin, director of the Englander Institute for Precision Medicine at Weill Cornell Medicine, and director of the precision medicine program at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center.|
NEW YORK, NY, July 8, 2016 — Columbia University Medical Center (CUMC) and Weill Cornell Medicine, in collaboration with NewYork-Presbyterian and NYC Health + Hospitals/Harlem, have been awarded a grant from the NIH for approximately $4 million in fiscal year 2016 to enroll participants in the Cohort Program of President Barack Obama's Precision Medicine Initiative (PMI) — a large-scale research effort to improve our ability to prevent and treat disease based on individual differences in lifestyle, environment and genetics. The five-year award is estimated to total $46.5 million, pending progress reviews and availability of funds.
CUMC is one of several medical centers that will provide expertise and infrastructure needed to launch the PMI Cohort Program. This landmark research effort aims to engage 1 million or more U.S. volunteers from the diversity of America in a significant research effort to improve our ability to advance precision medicine. The program seeks to extend the success of precision medicine in some cancers to many other diseases. Importantly, the program will focus not just on disease, but on ways to increase an individual's chances of remaining healthy throughout life.
"Columbia's university-wide commitment to pioneering research and clinical care in precision medicine coincides perfectly with the national priority established by President Obama to improve health and save lives, and we are deeply enthusiastic about being selected to help lead this effort," said Columbia University President Lee C. Bollinger. "We believe that in years to come, our society will benefit immeasurably from the advances in medical science that will emerge from this collaboration with this team of outstanding New York-based medical centers."
"Cornell University has a distinguished legacy of leading scientific discoveries that address our greatest healthcare challenges," said Hunter R. Rawlings III, interim president of Cornell University. "The launch of this collaboration marks a turning point in our effort to conquer disease and to translate research discoveries into life-changing impact for communities in New York and around the world."
"The PMI Cohort Program aligns perfectly with our own precision medicine effort, which we launched in 2015 in partnership with NewYork-Presbyterian and faculty from across Columbia University," said Lee Goldman, MD, Dean of the Faculties of Health Sciences and Medicine and Chief Executive, CUMC. "This award, in collaboration also with NewYork-Presbyterian, Weill Cornell, and our long-standing colleagues at NYC Health + Hospitals/Harlem, will extend our ongoing successes in taking an individualized approach to treating some cancers and rare genetic diseases to a broader range of human illnesses across the ethnically, culturally, and socioeconomically diverse population we serve. It will also enable us to make sure that research findings benefit our local population and beyond as quickly as possible."
"Precision medicine has the power to fundamentally change the way we understand and treat some of the world's most challenging diseases," said Dr. Augustine M.K. Choi, interim dean of Weill Cornell Medicine. "This NIH grant, and our critical work with colleagues from Columbia, NYC Health + Hospitals/Harlem and NewYork-Presbyterian, will ensure that we are better able to understand the key genetic and other biological drivers of disease and ultimately improve the lives of our patients. We are incredibly honored to be selected for this grant, and grateful to President Obama and the NIH for their bold vision."
"It's an incredible honor for our physicians and researchers to be a part of this historic initiative," said Dr. Steven J. Corwin, president and CEO of NewYork-Presbyterian. "As we delve into new research and discover new prevention and treatment options, this grant gives us a tremendous opportunity to continue to excel in our collective fight against cancer and all life-threatening diseases."
"The 'patient-powered' research that will result from our partnership with CUMC promises to help transform the way we achieve our mission to deliver equitable and culturally responsive care to the city's most vulnerable populations," said Ram Raju, MD, President and CEO of NYC Health + Hospitals. "Our collaboration with CUMC also underscores the critical role that the public hospital system plays in medical education and cutting-edge research to benefit the communities we serve."
"We are pleased and excited that the NIH has chosen the Columbia/Weill Cornell/NewYork-Presbyterian and Harlem Hospital collaboration as one of the partners in this ambitious and fundamentally important program," said Tom Maniatis, PhD, Director of the Columbia/NewYork-Presbyterian Precision Medicine Initiative and co-founder of the New York Genome Center. Dr. Maniatis is also the Isidore S. Edelman Professor and Chair of the Department of Biochemistry and Molecular Biophysics at CUMC. "This award is a validation of our commitment to realize the vision of precision medicine, which identifies relationships between genetic, lifestyle and environmental differences in individuals, and the prevention, diagnosis and treatment of human diseases. This grant also recognizes the successful establishment of the Institute for Genomic Medicine (IGM) at Columbia by its Director, Dr. David Goldstein, who has demonstrated the reality of a precision medicine-based approach to treating children with rare, previously undiagnosed genetic disorders."
"As doctors and scientists, we are committed to providing our patients with the very best, most cutting-edge care to ensure that illness isn't a barrier in their everyday lives," said Dr. Mark Rubin, director of the Englander Institute for Precision Medicine and the Homer T. Hirst III Professor of Oncology in Pathology at Weill Cornell Medicine, and director of the precision medicine program at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. "This grant will enable us to detect and delineate the key genetic drivers of disease across the diverse population of patients we serve — and move us closer to fulfilling the promise of precision medicine."
CUMC is one of four centers that have been designated as a regional PMI Cohort Program Healthcare Provider Organization (HPO). As an HPO, CUMC and its partners seek to enroll at least 150,000 volunteers by 2021. By engaging with a number of community organizations throughout New York City, this multicenter collaboration will help to ensure that participants in the PMI Cohort Program represent the geographic, ethnic, racial and socioeconomic diversity of the country that the NIH is hoping to achieve.
Principal Investigators include:
- David Goldstein, PhD, Contact Principal Investigator, professor of genetics and development and Director, Institute for Genomic Medicine
- Ali Gharavi, MD, professor of medicine and Chief, Division of Nephrology
- George Hripcsak, MD, MS, the Vivian Beaumont Allen Professor and Chair of the Department of Biomedical Informatics at CUMC and Director of Medical Informatics Services for NewYork-Presbyterian
- Mark Rubin, MD, director of the Englander Institute for Precision Medicine and the Homer T. Hirst III Professor of Oncology in Pathology Weill Cornell Medicine; director of precision medicine at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center.
- Rainu Kaushal, MD, chair of the Department of Healthcare Policy and Research at Weill Cornell Medicine; physician-in-chief of healthcare policy and research at NewYork-Presbyterian/Weill Cornell Medical Center
- Margaret Ross, MD, PhD, the Nathan Cummings Professor in Neurology, and a professor of neurology and of neuroscience at Weill Cornell Medicine
- Rhonda Trousdale, MD, Chief of Endocrinology, NYC Health + Hospitals/Harlem
Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cumc.columbia.edu or columbiadoctors.org.
NewYork-Presbyterian is one of the nation's most comprehensive healthcare delivery networks, focused on providing innovative and compassionate care to patients in the New York metropolitan area and throughout the globe. In collaboration with two renowned medical school partners, Weill Cornell Medicine and Columbia University College of Physicians & Surgeons, NewYork-Presbyterian is consistently recognized as a leader in medical education, groundbreaking research and clinical innovation.
NewYork-Presbyterian has four major divisions: NewYork-Presbyterian Hospital is ranked #1 in the New York metropolitan area by U.S. News and World Report and repeatedly named to the magazine's Honor Roll of best hospitals in the nation; NewYork-Presbyterian Regional Hospital Network is comprised of leading hospitals in and around New York and delivers high-quality care to patients throughout the region; NewYork-Presbyterian Physician Services connects medical experts with patients in their communities; and NewYork-Presbyterian Community and Population Health features the hospital's ambulatory care network sites and operations, community care initiatives and healthcare quality programs, including NewYork Quality Care, established by NewYork-Presbyterian, Weill Cornell and Columbia.
NewYork-Presbyterian is one of the largest healthcare providers in the U.S. Each year, nearly 29,000 NewYork-Presbyterian professionals deliver exceptional care to more than 2 million patients.
For more information, visit www.nyp.org and find us on Facebook, Twitter and YouTube.
Weill Cornell Medicine
Weill Cornell Medicine is committed to excellence in patient care, scientific discovery and the education of future physicians in New York City and around the world. The doctors and scientists of Weill Cornell Medicine — faculty from Weill Cornell Medical College, Weill Cornell Graduate School of Medical Sciences, and Weill Cornell Physician Organization — are engaged in world-class clinical care and cutting-edge research that connect patients to the latest treatment innovations and prevention strategies. Located in the heart of the Upper East Side's scientific corridor, Weill Cornell Medicine's powerful network of collaborators extends to its parent university Cornell University; to Qatar, where an international campus offers a U.S. medical degree; and to programs in Tanzania, Haiti, Brazil, Austria and Turkey. Weill Cornell Medicine faculty provide comprehensive patient care at NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian/Lower Manhattan Hospital and NewYork-Presbyterian/Queens. Weill Cornell Medicine is also affiliated with Houston Methodist. For more information, visit weill.cornell.edu.
About NYC Health + Hospitals
NYC Health + Hospitals is the largest public health care system in the nation committed to providing equal access to quality, culturally-responsive, affordable health care for all New Yorkers. The system is an integrated network of 11 hospitals, trauma centers, neighborhood health centers, nursing homes, and post-acute care centers. It includes a home care agency and a health plan, MetroPlus. The health system provides essential services to 1.2 million New Yorkers every year in more than 70 locations across the city's five boroughs. Its diverse workforce of more than 42,000 employees are uniquely focused on empowering New Yorkers, without exception, to live the healthiest life possible. NYC Health + Hospitals/Harlem is one of the system's 11 acute care hospitals. The 286-bed hospital provides a broad array of preventive, primary and acute care services. The hospital has an Area-Wide Burn Center, Level I Trauma Center, a Bariatric Surgery Center of Excellence, a designated Stroke and AIDS Center, and received the World Health Organization's UNICEF Baby Friendly designation. For more information, visit nychealthandhospitals.org and stay connected on or Twitter @NYCHealthSystem.
Posted July 8, 2016 2:45 PM | Permalink to this post